NASDAQ:FUSN

Fusion Pharmaceuticals Price Target, Predictions & Analyst Ratings

$4.00

+0.18 (+4.71%)

(As of 05/13/2022 03:20 PM ET)

Add

Compare

Today's Range: $4.00
▼
$4.02
50-Day Range: $3.82
▼
$7.86
52-Week Range: $3.71
▼
$10.40

Volume: 2 shs
Average Volume: 38,846 shs
Market Capitalization: $173.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: -0.66

Fusion Pharmaceuticals (NASDAQ:FUSN) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 4 Analyst Ratings

Analyst Price Target Consensus

$18.33
358.33% Upside

High PT	$19.00
Average PT	$18.33
Low PT	$17.00

Type	Current 5/16/21 to 5/16/22	1 Month Ago 4/16/21 to 4/16/22	3 Months Ago 2/15/21 to 2/15/22	1 Year Ago 5/16/20 to 5/16/21
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$18.33	$18.00	$18.00	$23.67
Price Target Upside	358.33% Upside	150.52% Upside	150.52% Upside	73.13% Upside

Get Fusion Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.

Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Fusion Pharmaceuticals (NASDAQ:FUSN) vs. Its Competitors

Type	Fusion Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.52
Consensus Rating	Buy	Buy	Buy
Price Target Upside	358.33% Upside	457.84% Upside	26.37% Upside
News Sentiment Rating	Positive News	Neutral News	Neutral News
MarketBeat Community Rating	Outperform Votes 19 67.86% Underperform Votes 9 32.14%	Avg. Outperform Votes 168 67.20% Avg. Underperform Votes 82 32.80%	Avg. Outperform Votes 837 69.29% Avg. Underperform Votes 371 30.71%

Fusion Pharmaceuticals (NASDAQ:FUSN) Analyst Ratings History

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/10/2022	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Price Target	Outperform	$20.00 ➝ $19.00	+361.16%
2/2/2022	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Dolliver Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
11/25/2021	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Walsh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00	+174.19%
8/18/2021	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Price Target	Overweight	$20.00 ➝ $19.00	+132.56%
12/17/2020	Bloom Burton Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Borovina Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
7/21/2020	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$25.00	+63.61%
7/21/2020	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

(Data available from 5/16/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Fusion Pharmaceuticals (NASDAQ:FUSN) Analyst Ratings Frequently Asked Questions

What is Fusion Pharmaceuticals's consensus rating and price target?: According to the issued ratings of 4 analysts in the last year, the consensus rating for Fusion Pharmaceuticals stock is Buy based on the current 4 buy ratings for FUSN. The average twelve-month price target for Fusion Pharmaceuticals is $18.33 with a high price target of $19.00 and a low price target of $17.00. Learn more on FUSN's analyst rating history.
Do Wall Street analysts like Fusion Pharmaceuticals more than its competitors?: Analysts like Fusion Pharmaceuticals stock more than the stock of other Medical companies. The consensus rating score for Fusion Pharmaceuticals is 3.00 while the average consensus rating score for medical companies is 2.72. Learn more on how FUSN compares to other companies.
Do MarketBeat users like Fusion Pharmaceuticals more than its competitors?: MarketBeat users like Fusion Pharmaceuticals stock more than the stock of other Medical companies. 67.86% of MarketBeat users gave Fusion Pharmaceuticals an outperform vote while medical companies recieve an average of 67.20% outperform votes by MarketBeat users.

Does Fusion Pharmaceuticals's stock price have much upside?: According to analysts, Fusion Pharmaceuticals's stock has a predicted upside of 197.46% based on their 12-month price targets.
What analysts cover Fusion Pharmaceuticals?: Fusion Pharmaceuticals has been rated by Wedbush in the past 90 days.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources